Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 04:58:53 GMT 2025
by
admin
on
Wed Apr 02 04:58:53 GMT 2025
|
| Protein Type | ENZYME |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
NH2W5DQ1DO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NH2W5DQ1DO
Created by
admin on Wed Apr 02 04:58:53 GMT 2025 , Edited by admin on Wed Apr 02 04:58:53 GMT 2025
|
PRIMARY | |||
|
O14746
Created by
admin on Wed Apr 02 04:58:53 GMT 2025 , Edited by admin on Wed Apr 02 04:58:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
VACCINE ANTIGEN->TARGET |
|
||
|
INHIBITOR -> TARGET |
Helenalin binds to Cys445 of telomerase
in the Michael-type addition reaction, disturbing recognition of the telomere DNA at the telomerase active site and causing suppression of the enzyme activity.
|
||
|
|
VACCINE ANTIGEN->TARGET |
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
||
|
INHIBITOR -> TARGET |
One compound is a trisubstituted acridine compound AS1410, a close analogue of BRACO-19. Synergistic behaviour was observed in both cell lines (MCF7 and A549) with both compounds in combination with cis-platin, but only when the ratio of AS1410:cis-platin is >1. In vivo tumour xenograft studies with the A549 lung cancer model and the trisubstituted acridine compound AS1410 showed only a modest anti-tumour effect when administered alone, but produced rapid and highly significant decreases in tumour volume when administered in combination with cis-platin.
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
||
|
ACTIVATOR OF EXPRESSION->TARGET |
|
||
|
|
ANTIGEN->TARGET |
|
||
|
|
ANTIGEN->TARGET |
T-CELL ANTIGEN
|
||
|
|
ANTIGEN->TARGET |
|
||
|
|
VACCINE ANTIGEN->TARGET |
|
||
|
ACTIVATOR OF EXPRESSION->TARGET |
|
||
|
ANTIGEN->TARGET |
PRESUMED T-CELL EPITOPE
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
||
|
VACCINE ANTIGEN->TARGET |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO_ACID_SUBSTITUTION | [1_707] | SITE_SPECIFIC | TYROSINE O-PHOSPHATE | 2R86C98KDX | ||
| AMINO_ACID_SUBSTITUTION | [1_227] [1_457] | SITE_SPECIFIC | DEXFOSFOSERINE | VI4F0K069V | ||
| METAL_BINDING | [1_712] [1_868] [1_869] | SITE_SPECIFIC | MAGNESIUM CATION | T6V3LHY838 |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|